XILIO THERAPEUTICS INC. - COMMON STOCK

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI 

19 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

16 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Dec 2024 16:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

07 Nov 2024 09:15:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

07 Nov 2024 09:05:00 By Nasdaq GlobeNewswire

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

30 Oct 2024 09:01:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

04 Oct 2024 09:05:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Oct 2024 16:15:03 By Nasdaq GlobeNewswire

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

28 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

08 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

13 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

14 May 2024 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

01 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

28 Mar 2024 07:05:00 By Nasdaq GlobeNewswire

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

28 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

28 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

31 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

08 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

07 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

09 Nov 2023 16:01:00 By Nasdaq GlobeNewswire